Phathom Pharmaceuticals, Inc. (PHAT) · Oct 23, 2026 · Other events
Exclusivity litigation — BDR challenges 10-year NCE exclusivity through May 3, 2032
Phathom disclosed a new lawsuit challenging VOQUEZNA’s 2032 FDA exclusivity, adding legal risk to its core commercial product.
Phathom is a commercial-stage GI biotech increasingly dependent on VOQUEZNA: second-quarter 2026 revenue reached $74.3 million, prescriptions continued growing, and management was targeting operating profitability beginning in the third quarter. The filing adds a new legal threat to that commercial ramp. BDR has sued FDA over the agency’s refusal to accept a generic application referencing VOQUEZNA. 〔0〕
The issue is the length of VOQUEZNA’s protected selling period. FDA previously recognized 10 years of new-chemical-entity exclusivity for the tablets through May 3, 2032. 〔1〕 If BDR ultimately prevails, FDA could accept and potentially approve a generic application earlier than Phathom expects, bringing competition into the company’s central revenue stream sooner. The filing does not say FDA has changed its position, and Phathom has not lost exclusivity today; the immediate change is the litigation overhang and the possibility of added legal expense and management distraction.
This is worse than the standing assumption, but not yet a change to current operations. The market had been working from the 2032 exclusivity date following FDA’s 2025 decision; BDR’s challenge makes that date less certain rather than shortening it immediately. The risk matters more because VOQUEZNA is the company’s commercial engine while its pipeline remains earlier-stage, including ongoing development in eosinophilic esophagitis and non-erosive GERD.
Bottom line: Phathom’s launch story remains intact for now, but the legal protection underpinning its revenue runway is no longer uncontested. The filing is a modest immediate setback because it introduces uncertainty around the 2032 generic-entry barrier without resolving the issue yet.
Q3 report, October 29
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!